Knee Osteoarthritis Clinical Trial
— DIA IIT_01Official title:
A Prospective, Randomized, Double-blinded, Multi-center, Trial to Evaluate Efficacy and Safety of Combination of Diacerein and Celecoxib Administered Orally in Patients With Knee Osteoarthritis
The purpose of this study is to evaluate the pain relief effect of Co-administration of Diacerein with Celecoxib in patients with knee osteoarthritis compared with single administration of each drug.
Status | Recruiting |
Enrollment | 90 |
Est. completion date | January 2, 2019 |
Est. primary completion date | January 2, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility |
Inclusion Criteria: 1. Subjects who voluntarily consented, after listening enough explanation for this study and investigational product. 2. Adult over 50 years of age. 3. At least one of the knee pain VAS score is 40mm or more. 4. Meets the ACR(American College of Rheumatology) criteria for diagnosis. (1) Confirmation of osteophytes on radiographic inspection. (2) One or more of the following three items. ? Age> 50 years ? Morning stiffness <30 minutes ? Crepitus 5. Patients who require medication for more than 12 weeks due to osteoarthritis symptoms. 6. Those who are able to follow the requirements of this clinical trial, such as being able to trace during the clinical trial period and to read and write the VAS questionnaire. 7. Those who weigh more than 40kg Exclusion Criteria: 1. Secondary knee osteoarthritis 2. Other inflammatory Knee Osteoarthritis (e.g. gout, rheumatoid arthritis, etc.) 3. Patients presenting with gastroesophageal reflux disease, peptic ulcer. 4. Helicobacter infected patients who have not been treated for eradication (recruitment if negative in re-examination after treatment). 5. Short bowel syndrome that can cause inflammatory bowel disease (ulcerative colitis, Crohn's disease) and drug absorption disorder. 6. Intestinal obstruction syndrome 7. Unexplained abdominal pain 8. ALT(Alanine aminotransferase) level of liver function test exceeded 5 times of reference range 9. Total bilirubin level exceeded 2 mg / dL 10. Serum albumin level less than 2 g / dL 11. Ascites 12. Hepatic encephalopathy 13. Hepatitis B, hepatitis C (excluding healthy carriers) or HIV positive 14. MDRD(Modification of Diet in Renal Disease) Estimated Glomerular filtration rate less than 60 mL / m2 15. Patients with hyperkalemia (over 5.5 meq / L) 16. history of asthma, acute rhinitis, nasal polyps, angioedema, urticaria or allergic reactions to aspirin or other non-steroidal anti-inflammatory drugs(including COX-2 inhibitors). 17. Malignant tumors other than basal cell or squamous cell carcinoma of the skin, CIN(Cervical Intraepitherial Neoplasia) and CIS(Carcinoma in situ) of the cervix, and intraepithelial carcinoma of other areas Within 5 years of consent date. 18. Medical history of hypersensitivity to the components of the investigational products. (The components of test drug 1 and 2, including the Rhein-based drug) 19. Patients with an allergic reaction to sulfonamide. 20. Patients with galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption. 21. Subjects who have not reached the prescribed period after receiving contraindicated medication or treatment before participation in this clinical trial. 22. Patients receiving contraindicated medication. 23. Alcohol and other drug abuse cases based on 6 months before screening. 24. Pregnant women or nursing mothers who are not willing to stop breastfeeding. 25. Female who do not fall into one or more of the following categories(In other words, only the following female can participate:) - (1) Menopause (non-therapy-induced amenorrhea of more than 12 months) Female - (2) Female infertility due to surgery (no ovaries and / or uterus) - (3) If you have sexual intercourse with only one male partner who has been confirmed to have no semen after fertilization. - (4) Female subjects who agreed to abstinence during the clinical trial period. - If the subject is assured of an abstinence throughout the trial period.(e.g. clergy) - However, intermittent abstinence (eg, contraception using ovulation period, symptothermal) or coitus interrupts is not a case of consent for abstinence. - (5) For women of childbearing age, the following methods or methods of contraception use the effective method of contraception to be used during the period of this clinical trial: - Oral contraceptive - The contraceptive patch - Intra uterine device (IUD) - contraceptive implant - contraceptive injection - intrauterine hormonal apparatus - Tubal ligation and infertility surgery 26. If 30 days have not elapsed after the date of signing of the previous clinical trial or currently participating in other clinical trials. 27. Patients who are scheduled for surgery during the clinical trial period or who have difficulties in completing the protocol during this clinical trial due to other reasons. 28. In addition to the above, other diseases that the investigator judges to be inappropriate. |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Korea University Guro Hospital | Seoul | |
Korea, Republic of | Seoul ST. Mary's Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
Whan-Seok Choi | Korea University Guro Hospital |
Korea, Republic of,
Li Z, Meng D, Li G, Xu J, Tian K, Li Y. Celecoxib Combined with Diacerein Effectively Alleviates Osteoarthritis in Rats via Regulating JNK and p38MAPK Signaling Pathways. Inflammation. 2015 Aug;38(4):1563-72. doi: 10.1007/s10753-015-0131-3. — View Citation
Martel-Pelletier J, Pelletier JP. Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis. 2010 Apr;2(2):95-104. doi: 10.1177/1759720X09359104. — View Citation
Nicolas P, Tod M, Padoin C, Petitjean O. Clinical pharmacokinetics of diacerein. Clin Pharmacokinet. 1998 Nov;35(5):347-59. Review. — View Citation
Panova E, Jones G. Benefit-risk assessment of diacerein in the treatment of osteoarthritis. Drug Saf. 2015 Mar;38(3):245-52. doi: 10.1007/s40264-015-0266-z. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | pain VAS score | Changes in pain VAS(Visual analogue scale) score before and after 12 weeks of drugs administration. (No pain score: 0, Worst pain score: 100) |
12 weeks after randomization | |
Secondary | pain NRS score | Changes in pain NRS(Numeric rating scale) score before and after 12 weeks of drugs administration. (No pain score: 0, Worst pain score: 10) |
12 weeks after randomization | |
Secondary | WOMAC index score | Changes in WOMAC(Western Ontario and mcmaster Universities Osteoarthritis Index) index score before and after 12 weeks of drugs administration (possible score range, Pain: 0-20, Stiffness: 0-8, Physical function: 0-68; Total Score range: 0-96 ('none' to 'extreme')) | 12 weeks after randomization | |
Secondary | GSRS index score | Changes in GSRS(Gastrointestinal symptom rating scale) index score before and after 12 weeks of drugs administration. (Score range: 0-45 ('none' to 'extreme')) |
12 weeks after randomization |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04651673 -
Prescribed Knee Brace Treatments for Osteoarthritis of the Knee (Knee OA)
|
||
Completed |
NCT05677399 -
Knee Osteoarthritis Treatment With Peloidotherapy and Aquatic Exercise.
|
N/A | |
Active, not recruiting |
NCT04043819 -
Evaluation of Safety and Exploratory Efficacy of an Autologous Adipose-derived Cell Therapy Product for Treatment of Single Knee Osteoarthritis
|
Phase 1 | |
Recruiting |
NCT06000410 -
A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee
|
Phase 3 | |
Completed |
NCT05014542 -
Needling Techniques for Knee Osteoarthritis
|
N/A | |
Recruiting |
NCT05892133 -
Prehabilitation Effect on Function and Patient Satisfaction Following Total Knee Arthroplasty
|
N/A | |
Recruiting |
NCT05528965 -
Parallel Versus Perpendicular Technique for Genicular Radiofrequency
|
N/A | |
Active, not recruiting |
NCT03472300 -
Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
|
||
Active, not recruiting |
NCT02003976 -
A Randomized Trial Comparing High Tibial Osteotomy Plus Non-Surgical Treatment and Non-Surgical Treatment Alone
|
N/A | |
Active, not recruiting |
NCT04017533 -
Stability of Uncemented Medially Stabilized TKA
|
N/A | |
Completed |
NCT04779164 -
The Relation Between Abdominal Obesity, Type 2 Diabetes Mellitus and Knee Osteoarthritis
|
N/A | |
Recruiting |
NCT04006314 -
Platelet Rich Plasma and Neural Prolotherapy Injections in Treating Knee Osteoarthritis
|
N/A | |
Recruiting |
NCT05423587 -
Genicular Artery Embolisation for Knee Osteoarthritis II
|
N/A | |
Enrolling by invitation |
NCT04145401 -
Post Market Clinical Follow-Up Study- EVOLUTION® Revision CCK
|
||
Active, not recruiting |
NCT03781843 -
Effects of Genicular Nerve Block in Knee Osteoarthritis
|
N/A | |
Recruiting |
NCT05974501 -
Pre vs Post Block in Total Knee Arthroplasty (TKA)
|
Phase 4 | |
Completed |
NCT05324163 -
Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis
|
Phase 3 | |
Completed |
NCT05529914 -
Effects of Myofascial Release and Neuromuscular Training for Pes Anserine Syndrome Associated With Knee Osteoarthritis
|
N/A | |
Recruiting |
NCT05693493 -
Can Proprioceptive Knee Brace Improve Functional Outcome Following TKA?
|
N/A | |
Not yet recruiting |
NCT05510648 -
Evaluation of the Effect of High-intensity Laser Therapy in Knee Osteoarthritis
|
N/A |